CHARLOTTE, N.C., Oct. 20, 2005 (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (OTCBB:CHTP), has successfully completed the Phase Ia trial of its leading drug candidate, CH-1504, an orally available, metabolically inert, anti-inflammatory and anti-tumor agent for the treatment of rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease and certain cancers. In this single ascending dose study, the compound was safe and well tolerated across a broad dose range with no clinically significant observations noted.
